References
- The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72::971–983.
- Walker FO. Huntington’s disease. Lancet. 2007;369:218–228.
- Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet. 1993;4:398–403.
- Wheeler VC, Chao MJ, et al.; Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium J-M. Identification of genetic factors that modify clinical onset of huntington’s disease. Cell. 2015;162::516–526.
- Jacobs M, Hart EP, van Zwet EW, et al. Progression of motor subtypes in huntington’s disease: a 6-year follow-up study. J Neurol. 2016;263:2080–2085.
- Ghosh R, Tabrizi SJ. Huntington disease. Handb Clin Neurol. 2018;147:255–278.
- Fusilli C, Migliore S, Mazza T, et al. Biological and clinical manifestations of juvenile Huntington’s disease: a retrospective analysis. Lancet Neurol. 2018;17:986–993.
- Chaganti SS, McCusker EA, Loy CT. What do we know about late onset huntington’s disease? J Huntingtons Dis. 2017;6:95–103.
- Rawlins MD, Wexler NS, Wexler AR, et al. The prevalence of huntington’s disease. Neuroepidemiology. 2016;46:144–153.
- Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083–1091.
- Warby SC, Visscher H, Collins JA, et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet. 2011;19:561–566.
- Wexler A. Stigma, history, and huntington’s disease. Lancet. 2010;376:18–19.
- Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother. 2018;18:51–63.
- Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in huntington’s disease. Physiol Rev. 2010;90:905–981.
- Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to huntington’s disease. Nat Rev Neurosci. 2005;6:919–930.
- Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89:910–926.
- Arrasate M, Finkbeiner S. Protein aggregates in huntington’s disease. Exp Neurol. 2012;238:1–11.
- Neueder A, Landles C, Ghosh R, et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in huntington’s disease patients. Sci Rep. 2017;7:1307.
- Landles C, Sathasivam K, Weiss A, et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in huntington disease. J Biol Chem. 2010;285:8808–8823.
- Sathasivam K, Neueder A, Gipson TA, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A. 2013;110:2366–2370.
- Slow EJ, van Raamsdonk J, Rogers D, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12:1555–1567.
- Slow EJ, Graham RK, Osmand AP, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A. 2005;102:11402–11407.
- Saudou F, Finkbeiner S, Devys D, et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55–66.
- Shin J-Y, Fang Z-H, Yu Z-X, et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol. 2005;171:1001–1012.
- Sica RE. Could astrocytes be the primary target of an offending agent causing the primary degenerative diseases of the human central nervous system? A hypothesis. Med Hypotheses. 2015;84:481–489.
- Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of huntington’s disease. Cell. 2000;101:57–66.
- Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2017;14:9–21.
- Evers MM, Toonen LJA, van Roon-Mom WMC. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015;87:90–103.
- clinicaltrials.gov. NCT02519036. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02519036
- Ionis Pharmaceuticals. IONIS-HTT Rx (RG6042) top-line data demonstrate significant reductions of disease-causing mutant huntingtin protein in people with huntington’s disease. [cited 2019 apr 1]. Available from: http://ir.ionispharma.com/node/23401/pdf
- Wang N, Gray M, Lu X-H, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease. Nat Med. 2014;20:536–541.
- clinicaltrials.gov. NCT03342053. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03342053
- clinicaltrials.gov. NCT03761849. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03761849
- clinicaltrials.gov. NCT03225833. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03225833
- clinicaltrials.gov. NCT03225846. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03225846
- Schulte J, Littleton JT. The biological function of the huntingtin protein and its relevance to huntington’s disease pathology. Curr Trends Neurol. 2011;5:65–78.
- DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104:17204–17209.
- McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008;105:5868–5873.
- Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005;102:5820–5825.
- Miniarikova J, Zanella I, Huseinovic A, et al. Design, characterization, and lead selection of therapeutic mirnas targeting huntingtin for development of gene therapy for huntington’s disease. Mol Ther Nucleic Acids. 2016;5:e297.
- Franich NR, Fitzsimons HL, Fong DM, et al. AAV vector–mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of huntington’s disease. Mol Ther. 2008;16:947–956.
- McBride JL, Pitzer MR, Boudreau RL, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther. 2011;19:2152–2162.
- Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther. 2009;17:1053–1063.
- Ramaswamy S, Kordower JH. Gene therapy for huntington’s disease. Neurobiol Dis. 2012;48:243–254.
- Dufour BD, Smith CA, Clark RL, et al. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in huntington’s disease mice. Mol Ther. 2014;22:797–810.
- Matsuzaki Y, Konno A, Mochizuki R, et al. Intravenous administration of the adeno-associated virus-PHP.B. capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci Lett. 2018;665:182–188.
- uniQure. Press release. [cited 2019 apr 1]. Available from: http://www.uniqure.com/Press%20Release_AMT_130%20IND%20approval%20-%20FINAL_1_22_19_PDF.pdf
- Voyager Therapeutics. Press release. [cited 2019 apr 1]. Available from: http://ir.voyagertherapeutics.com/phoenix.zhtml?c=254026&p=irol-newsArticle&ID=2277966
- CNBC. Feb 25, 2019. [cited 2019 apr 1]. Available from: https://www.cnbc.com/2019/02/25/roche-to-buy-gene-therapy-specialist-spark-in-4point3-billion-deal.html
- Geary RS, Norris D, Yu R, et al. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46–51.
- Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3:17071.
- Mittelman D, Moye C, Morton J, et al. Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci U S A. 2009;106:9607–9612.
- Garriga-Canut M, Agustín-Pavón C, Herrmann F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A. 2012;109:E3136–45.
- Cai L, Fisher AL, Huang H, et al. CRISPR-mediated genome editing and human diseases. Genes Dis. 2016;3:244–251.
- Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019. doi: 10.1038/s41580-019-0131-5
- Giannelli SG, Luoni M, Castoldi V, et al. Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery. Hum Mol Genet. 2018;27:761–779.
- Li P, Kleinstiver BP, Leon MY, et al. Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa. CRISPR J. 2018;1:55–64.
- Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21:121–131.
- Shin JW, Kim K-H, Chao MJ, et al. Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet. 2016;25:4566–4576.
- Yang S, Chang R, Yang H, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of huntington’s disease. J Clin Invest. 2017;127:2719–2724.
- clinicaltrials.gov. NCT03655678. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03655678
- clinicaltrials.gov. NCT03872479. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03872479
- La Spada AR. Finding a sirtuin truth in huntington’s disease. Nat Med. 2012;18:24–26.
- Jeong H, Then F, Melia TJ, et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell. 2009;137:60–72.
- Pallos J, Bodai L, Lukacsovich T, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of huntington’s disease. Hum Mol Genet. 2008;17:3767–3775.
- Smith MR, Syed A, Lukacsovich T, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of HUNTINGTON’S disease. Hum Mol Genet. 2014;23:2995–3007.
- Süssmuth SD, Haider S, Landwehrmeyer GB, et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease. Br J Clin Pharmacol. 2015;79:465–476.
- Reilmann R, Squitieri F, Priller J, et al. N02 safety and tolerability of selisistat for the treatment of huntington’s disease: results from a randomised, double-blind, placebo-controlled phase Ii trial. J Neurol Neurosurg Psychiatry. 2014;85:A102–A102.
- Oliveri V, Vecchio G. 8-Hydroxyquinolines in medicinal chemistry: a structural perspective. Eur J Med Chem. 2016;120:252–274.
- Rosas HD, Chen YI, Doros G, et al. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol. 2012;69:887–893.
- Xiao G, Fan Q, Wang X, et al. Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding. Proc Natl Acad Sci U S A. 2013;110:14995–15000.
- Cherny RA, Ayton S, Finkelstein DI, et al. PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6/2 mouse model of huntington’s disease. J Huntingtons Dis. 2012;1:211–219.
- Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in huntington’s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14:39–47.
- Prana Biotech. 2015. FDA end of phase 2 status update. [cited 2019 apr 1]. Available from: http://pranabio.com/wp-content/uploads/2015/02/150213_FDA-notification-FINAL.pdf
- Crotti A, Glass CK. The choreography of neuroinflammation in huntington’s disease. Trends Immunol. 2015;36:364–373.
- Björkqvist M, Wild EJ, Thiele J, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in huntington’s disease. J Exp Med. 2008;205:1869–1877.
- Politis M, Pavese N, Tai YF, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp. 2011;32:258–270.
- Wild E, Magnusson A, Lahiri N, et al. Abnormal peripheral chemokine profile in huntington’s disease. PLoS Curr. 2011;3:RRN1231.
- Crotti A, Benner C, Kerman BE, et al. Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014;17:513–521.
- Thöne J, Linker RA. Laquinimod in the treatment of multiple sclerosis: a review of the data so far. Drug Des Devel Ther. 2016;10:1111–1118.
- Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000–1009.
- Mishra MK, Wang J, Keough MB, et al. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann Clin Transl Neurol. 2014;1:409–422.
- Brück W, Pförtner R, Pham T, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012;124:411–424.
- Garcia-Miralles M, Hong X, Tan LJ, et al. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of huntington disease. Sci Rep. 2016;6:31652.
- Ehrnhoefer DE, Caron NS, Deng Y, et al. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Exp Neurol. 2016;283:121–128.
- clinicaltrials.gov. NCT02215616. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02215616
- Okuno T, Nakatsuji Y, Moriya M, et al. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2010;184:1499–1506.
- Smith ES, Jonason A, Reilly C, et al. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis. 2015;73:254–268.
- Hodges A, Strand AD, Aragaki AK, et al. Regional and cellular gene expression changes in human huntington’s disease brain. Hum Mol Genet. 2006;15:965–977.
- Southwell AL, Franciosi S, Villanueva EB, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of huntington disease. Neurobiol Dis. 2015;76:46–56.
- Leonard JE, Fisher TL, Winter LA, et al. Nonclinical Safety Evaluation of VX15/2503, a humanized IgG4 anti-SEMA4D antibody. Mol Cancer Ther. 2015;14:964–972.
- clinicaltrials.gov. NCT02481674. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02481674
- Vaccinex Inc. Press release Jan 2019. [cited 2019 apr 1]. Available from: http://ir.vaccinex.com/phoenix.zhtml?c=253837&p=irol-newsArticle&ID=2383558
- Denis HL, Lauruol F, Cicchetti F. Are immunotherapies for Huntington’s disease a realistic option? Mol Psychiatry. 2019;24:364–377.
- Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nat Rev Drug Discov. 2018;17:729–750.
- Shannon KM. Pridopidine for the treatment of Huntington’s disease. Expert Opin Investig Drugs. 2016;25:485–492.
- Sahlholm K, Århem P, Fuxe K, et al. The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptor. Mol Psychiatry. 2013;18:12–14.
- Hayashi T, Su T-P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131:596–610.
- Tang T-S, Slow E, Lupu V, et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in huntington’s disease. Proc Natl Acad Sci U S A. 2005;102:2602–2607.
- Hyrskyluoto A, Pulli I, Törnqvist K, et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway. Cell Death Dis. 2013;4:e646.
- de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:1049–1057.
- Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in huntington’s disease. Mov Disord. 2013;28:1407–1415.
- Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18:165–176.
- Sugars KL, Brown R, Cook LJ, et al. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington’s disease that contributes to polyglutamine pathogenesis. J Biol Chem. 2004;279:4988–4999.
- Leuti A, Laurenti D, Giampà C, et al. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2013;52:104–116.
- Giampà C, Laurenti D, Anzilotti S, et al. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of huntington’s disease. PLoS One. 2010;5:e13417.
- Omeros. 2014. Press release. [cited 2019 apr 1]. Available from: https://investor.omeros.com/news-releases/news-release-details/omeros-provides-update-pde10-inhibitor-program#
- clinicaltrials.gov. NCT02074410. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02074410
- clinicaltrials.gov. NCT01806896. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01806896
- clinicaltrials.gov. NCT02197130. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02197130
- Delnomdedieu M. 2016. PDE10A ICM trial. [cited 2019 apr 1]. Available from: http://chdifoundation.org/2016-conference/
- clinicaltrials.gov. NCT02342548. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02342548
- Rodrigues FB, Wild EJ. Clinical trials corner: september 2017. J Huntingtons Dis. 2017;6:255–263.
- Chabrier PE, Auguet M. Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent. CNS Drug Rev. 2007;13:317–332.
- clinicaltrials.gov. NCT02231580. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02231580
- Reilmann R, Rouzade-Dominguez M-L, Saft C, et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington’s disease. Mov Disord. 2015;30:427–431.
- Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6:61–67.
- Milnerwood AJ, Gladding CM, Pouladi MA, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in huntington’s disease mice. Neuron. 2010;65:178–190.
- Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for huntington’s disease. Parkinsonism Relat Disord. 2007;13:453–454.
- clinicaltrials.gov. NCT01458470. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01458470
- Huntington Study Group. Tetrabenazine as antichorea therapy in huntington disease: a randomized controlled trial. Neurology. 2006;66:366–372.
- Frank S, Testa CM, et al.; Huntington Study Group. Effect of deutetrabenazine on chorea among patients with huntington disease: a randomized clinical trial. JAMA. 2016;316:40–50.
- Bashir H, Jankovic J. Deutetrabenazine for the treatment of huntington’s chorea. Expert Rev Neurother. 2018;00:1–7.
- clinicaltrials.gov. NCT01897896. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01897896
- Fabio KM, Guillon CD, Lu S-F, et al. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013;102:2033–2043.
- Azevan Pharmaceuticals. Clinical candidates. [cited 2019 apr 1]. Available from: http://azevan.com/index.php/pages/clinical-candidates-2/
- clinicaltrials.gov. NCT02507284. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02507284
- Ariceta G, Giordano V, Santos F. Effects of long-term cysteamine treatment in patients with cystinosis. Pediatr Nephrol. 2019;34:571–578.
- Wilhelmus MMM, van Dam A-M, Drukarch B. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur J Pharmacol. 2008;585:464–472.
- Zainelli GM, Ross CA, Troncoso JC, et al. Transglutaminase cross-links in intranuclear inclusions in huntington disease. J Neuropathol Exp Neurol. 2003;62:14–24.
- Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002;8:143–149.
- Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington’s disease. J Neurosci. 2002;22:8942–8950.
- Pinto JT, Van Raamsdonk JM, Leavitt BR, et al. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of huntington disease. J Neurochem. 2005;94:1087–1101.
- Borrell-Pagès M, Canals JM, Cordelières FP, et al. Cystamine and cysteamine increase brain levels of BDNF in huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006;116:1410–1424.
- Verny C, Bachoud-Lévi A-C, Durr A, et al. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in huntington’s disease. Mov Disord. 2017;32:932–936.
- Di Biase L, Munhoz RP. Deep brain stimulation for the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2016;16:1067–1078.
- Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington’s disease: long-term results of a prospective open-label study. J Neurosurg. 2014;121:114–122.
- Wojtecki L, Groiss SJ, Ferrea S, et al. A prospective pilot trial for pallidal deep brain stimulation in huntington’s disease. Front Neurol. 2015;6:177.
- Ferrea S, Groiss SJ, Elben S, et al. Pallidal deep brain stimulation in juvenile huntington’s disease: local field potential oscillations and clinical data. J Neurol. 2018;265:1573–1579.
- Zittel S, Tadic V, Moll CKE, et al. Prospective evaluation of globus pallidus internus deep brain stimulation in huntington’s disease. Parkinsonism Relat Disord. 2018;51:96–100.
- Gruber D, Kuhn AA, Schoenecker T, et al. Quadruple deep brain stimulation in huntington’s disease, targeting pallidum and subthalamic nucleus: case report and review of the literature. J Neural Transm. 2014;121:1303–1312.
- clinicaltrials.gov NCT02535884. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02535884
- Colpo GD, Ascoli BM, Wollenhaupt-Aguiar B, et al. Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders. An Acad Bras Cienc. 2015;87:1435–1449.
- Choi K-A, Choi Y, Hong S. Stem cell transplantation for Huntington’s diseases. Methods. 2018;133:104–112.
- Colpo GD, Furr Stimming E, Teixeira AL. Stem cells in animal models of Huntington disease: A systematic review. Mol Cell Neurosci. 2019;95:43–50.
- Bachoud-Lévi AC, Rémy P, Nguyen JP, et al. Motor and cognitive improvements in patients with huntington’s disease after neural transplantation. Lancet. 2000;356:1975–1979.
- clinicaltrials.gov. NCT00190450. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT00190450
- Bachoud-Lévi A-C. From open to large-scale randomized cell transplantation trials in huntington’s disease: lessons from the multicentric intracerebral grafting in huntington’s disease trial (MIG-HD) and previous pilot studies. Prog Brain Res. 2017;230:227–261.
- isrctn.com. ISRCTN52651778. [cited 2019 apr 1]. Available from: http://www.isrctn.com/ISRCTN52651778
- Rodrigues FB, Quinn L, Wild EJ. Huntington’s disease clinical trials corner: january 2019. J Huntingtons Dis. 2019;8:115–125.
- clinicaltrials.gov. NCT02728115. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02728115
- clinicaltrials.gov. NCT03252535. [cited 2019 apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03252535
- Cho IK, Hunter CE, Ye S, et al. Combination of stem cell and gene therapy ameliorates symptoms in huntington’s disease mice. NPJ Regen Med. 2019;4:7.
- Nov 26, 2018. Chinese scientist claims to use crispr to make first genetically edited babies. New York Times. [Internet]. Available from: https://www.nytimes.com/2018/11/26/health/gene-editing-babies-china.html
- Zeun P, Scahill RI, Tabrizi SJ, et al. Fluid and imaging biomarkers for huntington’s disease. Mol Cell Neurosci. 2019;97:67–80.